Company intelligence / Profile preview

Myosin Therapeutics

Jupiter, Florida, United Statesmyosintherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MT-125 has received FDA orphan drug designation for malignant gliomas and is entering Phase 1b trials for glioblastoma. MT-110 is advancing to Phase 1 clinical trials for methamphetamine use disorder.

Therapeutic areas: OncologyPsychiatry
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

MT-125

3 more assets in the full pipeline.

Request access →

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Myosin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myosin Therapeutics.

Explore the full profile